Independent Financial Group LLC Invests $712,000 in Edwards Lifesciences Corporation $EW

Independent Financial Group LLC bought a new stake in Edwards Lifesciences Corporation (NYSE:EW) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 8,886 shares of the medical research company’s stock, valued at approximately $712,000.

Other institutional investors also recently bought and sold shares of the company. Evermay Wealth Management LLC increased its stake in Edwards Lifesciences by 4.0% in the 4th quarter. Evermay Wealth Management LLC now owns 3,304 shares of the medical research company’s stock worth $282,000 after purchasing an additional 128 shares during the period. Rehmann Capital Advisory Group lifted its position in Edwards Lifesciences by 2.1% in the fourth quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company’s stock valued at $546,000 after purchasing an additional 130 shares during the last quarter. Florida Trust Wealth Management Co boosted its stake in shares of Edwards Lifesciences by 1.5% during the fourth quarter. Florida Trust Wealth Management Co now owns 8,810 shares of the medical research company’s stock valued at $751,000 after purchasing an additional 132 shares during the period. McIlrath & Eck LLC boosted its stake in shares of Edwards Lifesciences by 14.6% during the fourth quarter. McIlrath & Eck LLC now owns 1,057 shares of the medical research company’s stock valued at $90,000 after purchasing an additional 135 shares during the period. Finally, Quadrant Capital Group LLC grew its holdings in shares of Edwards Lifesciences by 0.9% in the fourth quarter. Quadrant Capital Group LLC now owns 15,113 shares of the medical research company’s stock worth $1,288,000 after purchasing an additional 136 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Price Performance

Shares of EW stock opened at $84.41 on Wednesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42. Edwards Lifesciences Corporation has a fifty-two week low of $72.30 and a fifty-two week high of $96.29. The firm has a market cap of $48.61 billion, a P/E ratio of 44.90, a P/E/G ratio of 2.13 and a beta of 0.86. The business’s 50 day moving average price is $87.60 and its 200-day moving average price is $83.91.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The company had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.60 billion. During the same quarter in the prior year, the company earned $0.64 earnings per share. The firm’s revenue for the quarter was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, equities research analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other news, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the sale, the senior vice president owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. The trade was a 3.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $83.01, for a total transaction of $84,587.19. Following the sale, the vice president directly owned 33,934 shares in the company, valued at $2,816,861.34. The trade was a 2.92% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 45,577 shares of company stock valued at $3,855,527. 0.31% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

EW has been the topic of several analyst reports. Wall Street Zen downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Wolfe Research raised shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price target for the company in a research report on Wednesday, April 1st. Mizuho raised their price target on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a report on Wednesday, July 15th. Robert W. Baird boosted their price objective on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a research report on Friday, April 24th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences has a consensus rating of “Moderate Buy” and a consensus target price of $98.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.